TMDX Investor Alert: A Securities Fraud Class Action Lawsuit Has Been Filed Against TransMedics Group, Inc. (TMDX)
RADNOR, PA - March 17, 2025 ( NEWMEDIAWIRE) - The law firm of Kessler Topaz Meltzer & Check, LLP ( www.ktmc.com) informs investors that a securities class action lawsuit has been filed against TransMedics Group, Inc. ('TransMedics') ( NASDAQ: TMDX) on behalf of those who purchased or otherwise acquired TransMedics securities between February 28, 2023, and January 10, 2025, inclusive (the 'Class Period'). The lead plaintiff deadline is April 15, 2025.
CONTACT KESSLER TOPAZ MELTZER & CHECK, LLP:
You can also contact attorney Jonathan Naji, Esq. by calling (484) 270-1453 or by email at [email protected].
DEFENDANTS' ALLEGED MISCONDUCT:
The complaint alleges that, throughout the Class Period, Defendants made false and/or misleading statements and/or failed to disclose that: (1) TransMedics used kickbacks, fraudulent overbilling, and coercive tactics to generate business and revenue; (2) TransMedics engaged in unsafe practices and hid safety issues and generally lacked safety oversight; and (3) the foregoing subjected TransMedics to heightened risk of scrutiny and regulatory risk.
THE LEAD PLAINTIFF PROCESS:
TransMedics investors may, no later than April 15, 2025, seek to be appointed as a lead plaintiff representative of the class through Kessler Topaz Meltzer & Check, LLP or other counsel, or may choose to do nothing and remain an absent class member. A lead plaintiff is a representative party who acts on behalf of all class members in directing the litigation. The lead plaintiff is usually the investor or small group of investors who have the largest financial interest and who are also adequate and typical of the proposed class of investors. The lead plaintiff selects counsel to represent the lead plaintiff and the class and these attorneys, if approved by the court, are lead or class counsel. Your ability to share in any recovery is not affected by the decision of whether or not to serve as a lead plaintiff.
ABOUT KESSLER TOPAZ MELTZER & CHECK, LLP:
Kessler Topaz Meltzer & Check, LLP prosecutes class actions in state and federal courts throughout the country and around the world. The firm has developed a global reputation for excellence and has recovered billions of dollars for victims of fraud and other corporate misconduct. All of our work is driven by a common goal: to protect investors, consumers, employees and others from fraud, abuse, misconduct and negligence by businesses and fiduciaries. The complaint in this action was not filed by Kessler Topaz Meltzer & Check, LLP. For more information about Kessler Topaz Meltzer & Check, LLP please visit www.ktmc.com.
Kessler Topaz Meltzer & Check, LLP
Jonathan Naji, Esq.
(484) 270-1453
280 King of Prussia Road
Radnor, PA 19087
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Associated Press
2 days ago
- Associated Press
MicroStrategy Incorporated d/b/a Strategy (MSTR) Investors: July 15, 2025 Filing Deadline in Securities Class Action - Contact Kessler Topaz Meltzer & Check, LLP
RADNOR, PA - June 5, 2025 ( NEWMEDIAWIRE ) - The law firm of Kessler Topaz Meltzer & Check, LLP ( ) informs investors that a securities class action lawsuit has been filed against MicroStrategy Incorporated d/b/a Strategy ('Strategy') ( NASDAQ: MSTR ) on behalf of those who purchased or otherwise acquired Strategy securities between April 30, 2024, and April 4, 2025, inclusive (the 'Class Period'). The lead plaintiff deadline is July 15, 2025. CONTACT KESSLER TOPAZ MELTZER & CHECK, LLP: If you suffered Strategy losses, you may CLICK HERE or copy and paste the following link into your browser: You can also contact attorney Jonathan Naji, Esq. by calling (484) 270-1453 or by email at [email protected]. DEFENDANTS' ALLEGED MISCONDUCT: The complaint alleges that, throughout the Class Period, Defendants made materially false and misleading statements regarding Strategy's business, operations, and prospects. Specifically, Defendants made false and/or misleading statements and/or failed to disclose that: (1) the anticipated profitability of Strategy's bitcoin-focused investment strategy and treasury operations was overstated; (2) the various risks associated with bitcoin's volatility and the magnitude of losses Strategy could recognize on the value of its digital assets following its adoption of ASU 2023-08 were understated; and (3) as a result, Defendants' public statements were materially false and misleading at all relevant times. THE LEAD PLAINTIFF PROCESS: Strategy investors may, no later than July 15, 2025, seek to be appointed as a lead plaintiff representative of the class through Kessler Topaz Meltzer & Check, LLP or other counsel, or may choose to do nothing and remain an absent class member. A lead plaintiff is a representative party who acts on behalf of all class members in directing the litigation. The lead plaintiff is usually the investor or small group of investors who have the largest financial interest and who are also adequate and typical of the proposed class of investors. The lead plaintiff selects counsel to represent the lead plaintiff and the class and these attorneys, if approved by the court, are lead or class counsel. Your ability to share in any recovery is not affected by the decision of whether or not to serve as a lead plaintiff. Kessler Topaz Meltzer & Check, LLP encourages Strategy investors who have suffered significant losses to contact the firm directly to acquire more information. CLICK HERE TO SIGN UP FOR THE CASE OR GO TO: ABOUT KESSLER TOPAZ MELTZER & CHECK, LLP: Kessler Topaz Meltzer & Check, LLP prosecutes class actions in state and federal courts throughout the country and around the world. The firm has developed a global reputation for excellence and has recovered billions of dollars for victims of fraud and other corporate misconduct. All of our work is driven by a common goal: to protect investors, consumers, employees and others from fraud, abuse, misconduct and negligence by businesses and fiduciaries. The complaint in this action was not filed by Kessler Topaz Meltzer & Check, LLP. For more information about Kessler Topaz Meltzer & Check, LLP please visit CONTACT: Kessler Topaz Meltzer & Check, LLP Jonathan Naji, Esq. (484) 270-1453 280 King of Prussia Road Radnor, PA 19087 [email protected] May be considered attorney advertising in certain jurisdictions. Past results do not guarantee future outcomes. View the original release on
Entrepreneur
3 days ago
- Entrepreneur
3 High-Growth Stocks Traders Love and Investors Should Watch
These three small stocks carry significant risk, but that volatility has served traders well this year; now it's time for long-term investors to take a look This story originally appeared on MarketBeat Swing traders and long-term investors rarely find common ground. However, in 2025, three small stocks have been making traders rich. They each carry significant risk, but that volatility has served traders well this year. Each of these stocks has significantly outperformed the broader market, even some Magnificent Seven names like NVIDIA (NASDAQ: NVDA). However, just because these companies aren't well known doesn't mean they're not good long-term investments. Each of these stocks has a long-term thesis that can be compelling to buy-and-hold investors. That is, if they have the risk tolerance for speculative stocks. Plus, these are established companies that haven't been on investors' radar. The immediate risks are that, if the economy improves, swing traders may look for other targets. Plus, the outlook for stocks could turn negative in the second half. Right now, that doesn't seem likely, so here are three stocks investors should use to take a page out of traders' playbooks. This Company's First-Mover Advantage Is a Lifesaver [content-module:Forecast|NASDAQ:TMDX] TransMedics Group Inc. (NASDAQ: TMDX) is a small mid-cap company with a market cap of around $4.42 billion as of this writing. The commercial-stage medical technology company has a first-mover advantage in organ transplant logistics. Its Organ Care System (OCS) has proven benefits over cold storage. TransMedics has the only FDA-approved device for transporting multiple organ types (e.g., heart, liver, lungs). That's a scalable advantage that traders and investors can seize on. Traders frequently target medical stocks like TransMedics because it has a limited float of approximately 30 million shares which makes it prone to sharp price swings. Plus, with short interest above 25%, the stock is closely watched by traders looking for short squeeze opportunities. TMDX stock is up 110% in 2025. However, even though it's above analysts' consensus price target, it's still comfortably below its 52-week high. The company has a premium valuation, but it's growing revenue and earnings year-over-year (YOY). This Stock is Going Nuclear as Demand for Energy Increases [content-module:Forecast|NYSE:SMR] The next on this list is NuScale Power Corp. (NYSE: SMR). The ticker symbol is also an abbreviation for small modular reactors. These are expected to be the future of nuclear power as the world continues to look for ways to meet the growing demand for power. In fact, the company's VOYGR power module is the only such module approved by the U.S. Nuclear Regulatory Commission. This demand comes from artificial intelligence (AI) applications. But the stigma around nuclear energy is changing as governments and corporations realize it's one of the few truly clean forms of energy available. SMR stock is up about 78% in 2025, with most of that growth coming since May. That's when the company announced contracts from the U.S. government, which will serve as a long-term source of revenue. Like TMDX, traders are attracted to SMR stock for its smaller float and 20% short interest. Short interest is down slightly since news of the Department of Energy (DoE) contracts dropped. However, momentum traders like the fact that the stock has over 70% institutional ownership to provide ample liquidity. An Up-and-Coming Fintech With a Clear Mission [content-module:Forecast|NASDAQ:DAVE] Dave Inc. (NASDAQ: DAVE) is a financial technology (fintech) company that offers a banking app to help level the playing field for everyday Americans struggling with high fees from traditional banks. The company offers a personal financial management tool, Budget; ExtraCash as a short-term liquidity alternative, a job application portal to promote supplemental or temporary work, and Dave Banking, a digital checking and demand deposit account. The company is in a competitive market, but it's managing to increase its total addressable market (TAM) every year. While Dave is not yet profitable, it is growing YOY revenue and is on a path to profitability. DAVE stock is up over 120% in 2025, with the strongest gains coming since May, but it has grown over 2,600% since it was a penny stock in 2023. Before you make your next trade, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. Our team has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and none of the big name stocks were on the list. They believe these five stocks are the five best companies for investors to buy now... See The Five Stocks Here
Associated Press
4 days ago
- Associated Press
INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of West Pharmaceutical Services
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In West To Contact Him Directly To Discuss Their Options If you suffered losses exceeding $100,000 in West between February 16, 2023, and February 12, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] New York, New York--(Newsfile Corp. - June 4, 2025) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against West Pharmaceutical Services, Inc. ('West' or the 'Company') (NYSE: WST) and reminds investors of the July 7, 2025 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. [ This image cannot be displayed. Please visit the source: ] Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of millions of dollars for investors since its founding in 1995. See As detailed below, the complaint alleges that the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose that: (a) despite claiming strong visibility into customer demand and attributing headwinds to temporary COVID-related product destocking, West was in fact experiencing significant and ongoing destocking across its high-margin High-Value Products portfolio; (b) West's SmartDose device, which was purportedly positioned as a high-margin growth product, was highly dilutive to the Company's profit margins due to operational inefficiencies; (c) these margin pressures created the risk of costly restructuring activities, including the Company's exit from continuous glucose monitoring contracts with long-standing customers; and (d) as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially false and/or misleading or lacked a reasonable basis. The truth about this fraud was revealed over a series of disclosures culminating on February 13, 2025, when West issued extremely weak 2025 revenue and earnings forecasts. West attributed the disappointing guidance in part to contract manufacturing headwinds, including the loss of two major continuing glucose monitoring customers that had begun transitioning to in-house manufacturing of next-generation devices after West 'made the decision to not participate going forward as our financial thresholds cannot be achieved.' West also revealed that its SmartDose wearable injector devices would be 'margin-dilutive' in 2025 and that it would be 'taking steps to improve [its SmartDose] economics, and all options are on the table.' On this news, West's stock dropped $123.17 per share, a decline of 38 percent, to close at $199.11 on February 13, 2025. The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class who is adequate and typical of class members who directs and oversees the litigation on behalf of the putative class. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. Your ability to share in any recovery is not affected by the decision to serve as a lead plaintiff or not. Faruqi & Faruqi, LLP also encourages anyone with information regarding West's conduct to contact the firm, including whistleblowers, former employees, shareholders and others. To learn more about the West Pharmaceutical Services class action, go to or call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). Follow us for updates on LinkedIn, on X, or on Facebook. Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP ( ). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner. To view the source version of this press release, please visit
